Economic Impact of Intravenous Versus Subcutaneous Administration of Infliximab on Health System Finances and Operations
Publication
Article
Supplements and Featured PublicationsEconomic Impact of Intravenous Versus Subcutaneous Administration of Infliximab on Health System Finances and Operations
This clinical brief is supported by Celltrion Inc.